Genetic risk factors in patients with deep venous thrombosis, a retrospective case control study on Iranian population

Soudabeh Hosseini1, Ebrahim Kalantar2, Maryam Sadat Hosseini3, Shadi Tabibian3, Morteza Shamsizadeh4 and Akbar Dorgalaleh1*

Abstract

**Background:** Venous thromboembolism (VTE) could be manifested as deep venous thrombosis (DVT) or pulmonary embolism (PE). DVT is usually the more common manifestation and is usually formation of a thrombus in the deep veins of lower extremities. DVT could occur without known underlying cause (idiopathic thrombosis) which could be a consequence of an inherited underlying risk factor or could be a consequence of provoking events, such as trauma, surgery or acute illness (provoked thrombosis). Our aim in this study was to assess the impact of some previously reported genetic risk factors including, methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C, plasminogen activator inhibitor-1 (PAI-1) 4G/5G, prothrombin 20210 and FV Leiden on occurrence of DVT in a population of Iranian patients.

**Methods:** This long-term study was conducted on 182 patients with DVT and also 250 age and sex matched healthy subjects as control group. The diagnosis of DVT was based on patient’s history, clinical findings, D-dimer test, and confirmed by Doppler ultrasonography. After confirmation of DVT, both groups were assessed for the five mentioned mutations. The relationship between mutations and predisposition to DVT was calculated by using logistic regression and expressed as an OR with a 95% confidence interval (CI).

**Results:** Our results revealed that FV Leiden (OR 6.7; 95% CI = 2.2 to 20.3; P = 0.001), MTHFR C677T (OR 6.0; 95% CI = 2.2 to 16.4; P < 0.001), MTHFR A1298C (OR 8.3; 95% CI = 4.4 to 15.8; P < 0.001), and PAI-1 4G/5G (OR 3.8; 95% CI = 2.1 to 7.2; P < 0.001) mutations were all significantly associated with an increased risk of DVT. Prothrombin 20210 was found in none of the patients and controls.

**Conclusion:** Our findings suggest that genetic risk factors have a contributory role on occurrence of DVT.

**Keywords:** Deep venous thrombosis, Plasminogen activator inhibitor-1, FV Leiden, Prothrombin20210, Methylenetetrahydrofolate reductase

Background

Venous thromboembolism (VTE) which is manifested either as deep venous thrombosis (DVT) or pulmonary embolism (PE) is the third most frequent cardiovascular disorder after myocardial infarction and stroke. DVT is the thrombotic obstruction of deep veins in the lower extremities, and is a significant cause of mortality and morbidity. According to the studies, 1 in 1000 individuals in old age population is complicated by DVT, annually [1–3].

DVT is a multi-factorial disorder which may occur following a combination of some acquired conditions including surgical procedures, hormonal therapy, trauma, cancer, or immobilization condition (hospitalization), and inherited risk factors [1]. Based on the studies, genetic factors are responsible for approximately 60% DVT cases [4]. Factor V (FV) Leiden which is the most common cause of inherited thrombophilia, predisposes patients to DVT because of resistance to protein C. Prothrombin 20210, another
common cause of hereditary thrombophilia, is also a risk factor for DVT [5]. Two common polymorphisms in methylene tetrahydrofolate reductase (MTHFR) gene including C677T and A1298C, lead to decreased enzyme activity and therefore elevation of homocysteine level. Several studies have shown that these two polymorphisms might be associated with DVT due to hyperhomocysteinemia [6–9]. Another polymorphism which is known as a risk factor for DVT is Plasminogen activator inhibitor-1 (PAI-1) 4G/5G. The 4G allele is associated with a higher level of PAI-1 in plasma which in turn results in a decreased fibrinolysis activity and therefore a higher tendency to thrombus formation [8–10].

There are several studies in the literature which assessed the genetic risk factors of DVT in different ethnical populations [11–15]. In this regard the aim of the current study was to analyze some previously reported genetic risk factors including, MTHFR C677T and A1298C, PAI-1 4G/5G, Prothrombin 20210 and FV Leiden on occurrence of DVT in Iranian population.

Patients and methods

Study population, and data collection

This long-term retrospective study was conducted from June 2009 to July 2013 on 182 patients with DVT and also 250 age and sex matched healthy individuals as control group who referred to Clinical laboratory. The mean age of patients was 38.3 ± 15.4 years (median = 34, range = 81), 67.6 % of patients were female and 32.4 % were male. We included patients with confirmed DVT who experienced thrombosis more than once with no specific reason. The exclusion criteria were defined as incomplete medical history. For control group we randomly selected 250 healthy individuals with no history of thrombosis who were as similar as possible to the patients group regarding age and sex (using independent t-test, \( P = 0.4 \)). The mean age of controls was 39.7 ± 16.4 years (median = 36, range = 87), 65.5 % of patients were female and 34.5 % were male. A written consent was obtained from all the participants and the study was approved by the medical ethics committee of local ethical committee.

Initially each suspected patient was physically examined by physician and also was interviewed by a trained staff about their medical history. The diagnosis of venous thromboembolic disease was based on patient’s history, clinical findings and D-dimer test. Finally DVT was confirmed by Doppler ultrasonography. In addition, all participants were asked to complete a standardized questionnaire on acquired risk factors of venous thrombosis.

DNA analysis

Blood samples were collected early in the morning in EDTA anticoagulant. Collected whole blood samples were stored at −20 °C for DNA extraction in an appropriate time. In the next step DNA was extracted from thawed whole bloods using QIAAMP DNA blood kit (Qiagen, Germany). The quality and quantity of the extracted DNA was determined by spectrophotometer and also by means of agarose gel electrophoresis. Isolated DNA samples were then stored at −70 °C for long-time usage.

Analysis of PAI-1 polymorphism was performed by amplifying the promoter gene flanking region for 4G/5G polymorphism. The PCR products of 148-bp DNA fragments were digested with Bse RI (MBI Fermentas) according to the protocol provided by the manufacturer. Digestion products were subjected to electrophoresis on 2 % agarose gel. The presence of 110- and 38-bp DNA fragments indicated the 4G allele, while the 148-bp fragment indicated the 5G allele. Patients were also screened for Factor V Leiden, prothrombin 20210, MTHFRA1298C and MTHFR C677T gene mutations by procedures which described elsewhere [16–19].

Statistical methods

Results were reported as mean ± standard deviation (SD) for quantitative variables and percentages for categorical variables. All the statistical analyses were performed by SPSS software. The relationship between the PAI-1, MTHFR and FV Leiden gene polymorphisms and DVT was calculated using logistic regression and expressed as an odd ratio (OR) with a 95 % confidence interval (CI). The combined effect of these polymorphisms on the risk of DVT was also assessed by logistic regression. For this purpose we analyzed the risk of DVT in combined inheritance of each two polymorphisms, either in heterozygous or homozygous manner, in comparison with the single inheritance of the related mutations (as a reference). The \( P \) values less than 0.05 were considered as statistically significant.

Results

Characteristics of the study population

The youngest patient was a 1 year-old female and the oldest one was also an 82 year-old female. Demographic data of patients with DVT is shown in Table 1.

Prothrombin 20210, Factor V Leiden, MTHFR and PAI-1 mutations analysis

Distribution of FV Leiden, MTHFRC677T, MTHFRA1298C, and PAI-1 4G/5G among DVT patients and controls are indicated in Table 2. Molecular analysis of study population revealed that in the patients group, 8 (4.4 %) patients (1 male and 7 female) were homozygous for FV Leiden and 10 (5.5 %) (5 males and 5 females) were carriers for this
mutation. Prevalence of FV Leiden was 9.9 % in patients and 1.6 % in controls. Although none of the controls was homozygous for FV Leiden. Statistical analysis revealed a significant association between FV Leiden mutation and DVT (OR 6.7; 95 % CI = 2.2 to 20.3; P = 0.001). Out of 182 patients 17 (9.3 %) (2 males and 15 females) were homozygous for MTHFRC677T and 3 (1.6 %) were carriers. Among controls 5 were detected with MTHFRC677T mutation, 3 in heterozygous and 2 in homozygous state. The prevalence of this mutation was 10.9 % in patients and 2 % in healthy controls, and therefore the association between MTHFRC677T and DVT were statistically significant (OR 6.0; 95 % CI = 2.2 to 16.4; P < 0.001). Among the studied mutations it seems that MTHFRA1298C has the highest prevalence in patients with DVT (31.3 %) and the majority of patients with this mutation were heterozygote (30.2 %). The association between MTHFRA1298C and DVT were also significant (OR 8.3; 95 % CI = 4.4 to 15.8; P < 0.001). PAI-1 mutation was found in 38 patients with a prevalence of 20.9 %. Thirty four (18.7 %) out of 38 patients were carriers and only 4 (2.2 %) were homozygous. This mutation was also found in 16 (6.4 %) healthy individuals in heterozygous pattern. A significant association was also found between PAI-1 4G/5G and the occurrence of DVT (OR 3.8; 95 % CI = 2.1 to 7.2; P < 0.001). However prothrombin 20210 was found in none of the patients and controls. These findings are in agreement with the study of Rahimi et al. who showed that FV Leiden but not Prothrombin 20210 is a risk factor for DVT in western Iran [22].

Discussion

Inherited thrombophilia gene mutations are known to have a contributory role in the occurrence of VTE which is clinically manifested by DVT and/or PE [1]. According to the literature the incidence of VTE varies in different races. There have been several studies with the intention of investigating genetic risk factors contributing to DVT in different populations. Akhter et al. indicated a higher prevalence of 4G allele in patients experiencing DVT in Indian Asian population [10]. A similar result was also reported by Shammaa et al. in Lebanese population [20].

In a study on Croatian population by Alfrevic et.al FV Leiden was reported as the highest and prothrombin 20210 as the second most frequent thrombophilia gene mutations [11]. In this regard, we designed this study to investigate the association of five important polymorphisms with the occurrence of DVT in Iranian patients. The incidence of DVT in our studied population was approximately 2 fold higher in females than in males, a finding consistent with the study of Janbabai et al. on northern Iran which noted that DVT is more prevalent in females [21]. According to our results FV Leiden, MTHFRC677T, MTHFRA1298C, and PAI-1 4G/5G mutations were all significantly associated with an increased risk of DVT; but prothrombin 20210 was found in none of the patients and controls. These findings are in agreement with the study of Rahimi et al. who showed that FV Leiden but not Prothrombin 20210 is a risk factor for DVT in western Iran [22]. In contrast, there are some reports which failed to find the contributory role of FV Leiden on occurrence of DVT in Iranian patients [23, 24]. In the study conducted by Hajsadeghi et al. FV Leiden and Prothrombin 20210 were introduced as uncommon genetic causes of DVT in Iranian population from Esfahan city. They found no significant association between these two polymorphisms and DVT [23]. These results were supported by the study of Pourghysari et al. on VTE in central Iran [24]. In a Meta analysis study by Simone et al. involving 11,000 cases and 21,000 controls FV Leiden and Prothrombin 20210 were indicated as moderate risk factors of VTE and the risk was increased in heterozygote carriers of FV Leiden or Prothrombin 20210, however they found no significant association with DVT and homozygous pattern of MTHFRC677T [25]. These contradicting data may reflect the different incidence of various thrombophilia polymorphisms in different populations. Based on studies in

| Table 1 Demographic data of patients with DVT |
|------------------------------------------------|
| FV Leiden | MTHFR C677T | MTHFR 1298 | PAI-1 |
|-----------|-------------|------------|-------|
| Homo (AA) | Homo (TT)   | Homo (CC)  | Homo (4G/4G) |
| Sex       | Hetero (GA) | Hetero (CT) | Hetero (AC) |
|-----------|-------------|------------|-------|
| Male      | 1 (12.5 %)  | 2 (11.8 %) | 3 (100 %) | 1 (25 %) |
|           | 5 (50 %)    | 3 (100 %)  | 16 (29 %) | 5 (14.7 %) |
| Female    | 7 (87.5 %)  | 15 (88.2 %)| 2 (100 %) | 3 (75 %) |
|           | 5 (50 %)    | 0 (0)      | 39 (71 %) | 29 (85.3 %) |
| Age (year)| (mean ± SD) | Median     | Range  |
|-----------|-------------|------------|--------|
| Male      | 40.3 ± 12.9 | 36.3 ± 13.4| 35     |
|           | 42.1 ± 11.2 | 53.3 ± 9.7 | 52     |
| Female    | 36          | 25 ± 2.8   | 25     |
|           | 44.5        | 31.3 ± 13.1| 19     |
|           | median      | 34.5 ± 16  | 9       |
|           | range       | 34.5 ± 11.6| 35     |

Hosseini et al. Thrombosis Journal (2015) 13:35
| Table 2 Distribution of assessed polymorphisms among DVT patients and controls |
|---------------------------------------------------------------|
|                                                             |
| VV leiden | MTHFRC677T | MTHFR A1298C | PAI-1 |
| Non mutant | Hetero | Homo | Non mutant | Hetero | Homo | Non mutant | Hetero | Homo |
| Patients with DVT (n = 182) |
| 164 (90.1 %) | 10 (5.5 %) | 8 (4.4 %) | 162 (89.0 %) | 3 (1.6 %) | 17 (9.3 %) | 125 (68.7 %) | 55 (30.2 %) | 2 (1.1 %) | 144 (79.1 %) | 34 (18.7 %) | 4 (2.2 %) |
| Control group (n = 250) |
| 246 (98.4 %) | 4 (1.6 %) | 0 (0) | 245 (98 %) | 3 (1.2 %) | 2 (0.8 %) | 237 (94.8 %) | 9 (3.6 %) | 4 (1.6 %) | 234 (93.6 %) | 16 (6.4 %) | 0 (0 %) |
| OR | 6.7 | 6.0 | 8.3 | 3.8 |
| 95 % CI | 2.2 to 20.3 | 2.2 to 16.4 | 4.4 to 15.8 | 2.1 to 7.2 |
| P. value | 0.001 | <0.001 | <0.001 | <0.001 |
different parts of Iran it seems that Prothrombin 20210 is not a significant genetic factor for DVT in Iranian population and there seems to be no consistent findings on FV Leiden.

There are also studies suggesting that combined inheritance of different thrombophilia mutations has a significant effect on the occurrence of DVT [26, 27], while we did not find statistically significant difference between co-inheritance of each two polymorphisms and the single inheritance of the related mutations.

A significant limitation of our study was the lack of data regarding clinical characteristics of the studied population such as localization of DVT and acquired risk factors. Considering that DVT is a multi-factorial disorder arising from acquired and genetic risk factors, it is better to assess both clinical and genetic conditions in DVT patients which lead to a more comprehensive and reliable conception of its etiology.

Conclusion
Our findings suggest that genetic risk factors have a contributory role on occurrence of DVT. But still large studies are required to determine the most important underlying prothrombophilic gene mutations which lead to DVT in Iranian population.

Abbreviations
VTE: Venous thromboembolism; DVT: Deep venous thrombosis; PE: Pulmonary embolism; MTHFR: Methylenetetrahydrofolate reductase; PAI-1: Plasminogen activator inhibitor-1; CI: Confidence interval; FV: Factor V.

Competing interests
The authors declare that they have no competing interests.

Authors' contributions
Akbar Dorgalaleh designed the research and performed the molecular analysis, Shadi Tabibian contributed to molecular analysis, Akbar Dorgalaleh and Maryam Sadat Hosseini wrote the manuscript and performed the statistical analysis, Shaban Alizadeh revised the manuscript. All authors read and approved the final manuscript.

Acknowledgments
We are indebted to all of the patients who agreed to participate in this study.

References
1. Esmon CT. Basic mechanisms and pathogenesis of venous thrombosis. Blood Rev. 2009;23(5):225–9.
2. Goldhaber SZ. Venous thromboembolism: epidemiology and magnitude of the problem. Best Pract Res Clin Haematol. 2012;25(2):335–42.
3. Shaheen K, Alraies MC, Alraies AH, Christie R. Factor V Leiden: how great is the risk of venous thromboembolism? Clev Clin J Med. 2012;79(4):265–72.
4. Souto JC, Almasy L, Barreto MJ, Bondy AE, De Sanctis V, Doneima M, et al. Genetic susceptibility to thrombosis and its relationship to physiological risk factors: the GAIT study. Am J Hum Genet. 2006;78(6):1452–9.
5. Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis. N Engl J Med. 2001;344(16):1222–31.
6. Pop TR, Vesa SC, Trifa AP, CRISAN S, Buzoianu AD. PAI-1 4G/5G and MTHFR C677T polymorphisms increased the accuracy of two prediction scores for the risk of acute lower extremity deep vein thrombosis. Rom J Morphol Embryol. 2014;55(1):153.
7. Sprioski I, Kedev S, Atonov S, Anov T, Kostevska M, Dzehekova-Stojkova S, et al. Methyleneetetrahydrofolate reductase (MTHFR-677 and MTHFR-1298) genotypes and haplotypes and plasma homocysteine levels in patients with occlusive artery disease and deep venous thrombosis. Acta Biochim Pol. 2008;55(3):587–94.
8. JURCIUT R, POP I, Corui D, Grasu M, ZIL’STEANU D, Giucul S, et al. Compound heterozygosity for the C677T and A1298C mutations of the MTHFR gene in a case of hyperhomocysteinemia with recurrent deep vein thrombosis at young age. Rom J Intern Med. 2008;46(3):255–9.
9. Oztuzu S, Ergun S, Ulusali M, Nacaralhaya G, Içliy YZ, Içlıy M, et al. Evaluation of Factor V G1691A, prothrombin G20210A, Factor XIII V34L, MTHFR A1298C, MTHFR C677T and PAI-1 4G/5G genotype frequencies of patients subjected to cardiovascular disease (CVD) panel in south-east region of Turkey. Mol Biol Rep. 2014;41(6):3671–6.
10. Ahlter MS, Bivas A, Ranjan R, Meena A, Yadav BK, Sharma A, et al. Plasminogen activator inhibitor-1 (PAI-1) gene 4G/5G promoter polymorphism is seen in higher frequency in the Indian patients with deep vein thrombosis. Clin Appl Thromb Hemost. 2010;16(2):184–8.
11. Alferevic Z, Simundic AM, Nikolac N, Sobocan N, Alferevic I, Stefanovic M, et al. Frequency of Factor II G20210A, factor V Leiden, MTHFR C677T and PAI-1 5G/4G polymorphism in patients with venous thromboembolism: Croatian case-control study. Biochem Med. 2010;20(2):129–35.
12. Pai N, Ghosh K, Shetty S. Cause of deep venous thrombosis and pulmonary embolism in young patients from India as compared with other ethnic groups. Blood Coagul Fibrinolysis. 2012;23(4):257–61.
13. Bonduel M, Schuclatti G, Hepner M, Pieroni G, Torres AF, Mardaraz C, et al. Factor V Leiden and prothrombin gene G20210A mutation in children with cerebral thromboembolism. Am J Hematol. 2003;73(2):81–6.
14. Kesely R. Factor V:Leiden mutation: a common risk factor for venous thrombosis among Lebanese patients. Thromb J. 2012;doi:10.1186/1478-811X-10-28.
15. Guzman N, Laras F, Salazar LA. Influence of American mitochondrial DNA haplogroups on thrombosis susceptibility and frequency of four genetic prothrombotic variants in Southern Chilean subjects. Clin Chim Acta. 2010;411(5):444–5.
16. Beauchamp NJ, Daly ME, Hampton KK, Cooper PC, Preston FE, Peake IR. High prevalence of a mutation in the factor V gene within the UK population: relationship to activated protein C resistance and familial thrombosis. Br J Haematol. 1994;88(1):219–22.
17. Naderi M, Alizadeh S, Kazemi A, Tabibian S, Zaker F, Bamedi T, et al. Central nervous system bleeding in pediatric patients with factor XII deficiency: A study on 23 new cases. Hematology. 2015;20(2):112–8.
18. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996;88(10):3698–703.
19. Zappacosta B, Romano L, Persichilli S, Cutrone LA, Graziano M, Vitrani A, et al. Genotype prevalence and allele frequencies of 5,10-methyleneetetrahydrofolate reductase (MTHFR- C677T and A1298C) polymorphisms in Italian newborns. Lab Med. 2009;40(12):732–6.
20. Shamma MA, Sabbagh AS, Taher AT, Zaariar GS, Mahfouz RA. Plasminogen activator inhibitor-1 (PAI-1) gene 4G/5G alleles frequency distribution in the Lebanese population. Mol Biol Rep. 2008;35(3):453–7.
21. Janbabai G, Taghipour M, Sharifian R, Sharifpour A, Davoodi M, Farzamandfar T, et al. Survey of thrombophilia risk factors and markers in patients with deep vein thrombosis in Mazandaran Province, Northern Iran. Adv Biol Res. 2013;7(4):139–43.
22. Rahimi Z, Mozafari H, Shahrizai-Ahmedi A, Alimogaddam K, Ghasemzadeh A, Aznab M, et al. Deep venous thrombosis and thrombophilic mutations in western Iran association with factor V Leiden. Blood Coagul Fibrinolysis. 2010;21(3):385–8.
23. Hajiadeghi S, Kerman SRJ, Joodat R, Hejratie M, Vaferi H, Farsi N, et al. Deep vein thrombosis, demographic characteristics and risk factors in Iran. Galen Med J. 2013;2(4):135–40.

24. Pourghaysari B, Boroujeni HR, Hasheminia AM, Drees F. PLA2 polymorphism of platelet glycoprotein IIb/IIIa but not Factor V Leiden and prothrombin G20210A polymorphisms is associated with venous thromboembolism and more recurrent events in central Iran. Blood Coagul Fibrinolysis. 2013;24(5):471–6.

25. Simone B, De Stefano V, Leoncini E, Zacho J, Martinelli I, Emmerich J, et al. Risk of venous thromboembolism associated with single and combined effects of Factor V Leiden, Prothrombin 20210A and Methylene tetrahydrofolate reductase C677T: a meta-analysis involving over 11,000 cases and 21,000 controls. Eur J Epidemiol. 2013;28(8):621–47.

26. Simsek E, Yesilyurt A, Pinarli F, Eyerci N, Ulus AT. Combined genetic mutations have remarkable effect on deep venous thrombosis and/or pulmonary embolism occurrence. Gene. 2014;536(1):171–6.

27. Almawi WY, Tamim H, Kreidy R, Timson G, Rahal E, Nabulsi M, et al. A case control study on the contribution of factor V-Leiden, prothrombin G20210A, and MTHFR C677T mutations to the genetic susceptibility of deep venous thrombosis. J Thromb Thrombolysis. 2005;19(3):189–96.